|
|
Article: Implications of Vytorin approval in USA assessed by Wood Mackenzie.
- Article from:
- Pharma Marketletter
- Article date:
- August 16, 2004
CopyrightCOPYRIGHT 2004 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
At the end of last month, the US Food and Drug Administration approved the marketing of the new combination cholesterol-lowering drug, Merck & Co and Schering-Plough's Vytorin (ezetimibe and simvastatin; Marketletter August 2) and analysts at pharmaceutical consulting group Wood Mackenzie have issued a report on what this means for the companies, Merck in particular, and the therapeutic sector overall.
While this represents a new entrant to the US cholesterol-lowering market, the constituents of Vytorin are already available - ezetimibe as Zetia and simvastatin as Zocor, the report points out.
The approval of Vytorin comes at a time of increased ...